SavedAdd your journal

Journals / İzmir Tepecik Eğitim Hastanesi Dergisi / 2015 / Cilt: 25 - Sayı: 1

Clues and Pitfalls in the evaluation of HER2

HER2 değerlendirmesindeki ipucu ve tuzaklar

AYŞE GÜLDEN DİNİZ ÜNLÜ
Çiğdem IRKKAN
Canan KELTEN
SELVER ÖZEKİNCİ
Pages
7–12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The aim of this review is to discuss the important pitfalls and clues for HER2 assessment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Human epidermal growth factor receptor 2 (HER2) is a member of the epidermal growth factor receptor family, having tyrosine kinase activity.
📊
Key Findings & Data:Amplification of HER2 is especially investigated in breast, gastric, and gastroesophageal cancers.
💡
Conclusion & Impact:The aim of this review is to discuss the important pitfalls and clues for HER2 assessment.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Human epidermal growth factor receptor 2 (HER2) is a member of the epidermal growth factor receptor family, having tyrosine kinase activity. Amplification of this receptor initiates some signaling pathways leading to cell proliferation and carcinogenesis. Amplification of HER2 is especially investigated in breast, gastric, and gastroesophageal cancers. Introduction of targeting therapies for HER2 has dramatically influenced the outcome of patients with HER2 positive cancers. Currently HER2 testing is realised by different methods and it is crucial to standardize testing techniques to evaluate HER2 status accurately. Still several controversial issues related to HER2 testing are on the agenda in both breast and in gastric cancers, despite decades of experience. The aim of this review is to discuss the important pitfalls and clues for HER2 assessment.

Özet

İnsan epidermal büyüme faktör reseptörü 2 (HER2), tirozin kinaz aktivitesine sahip epidermal büyüme faktör reseptör ailesinin bir üyesidir. Bu reseptörün çoğalması hücre proliferasyonu ve karsinogeneze yol açan bazı sinyal yolaklarını başlatır. HER2 amplifikasyonu özellikle meme ve mide/özofagus-mide bileşke tümörlerinde saptanmaktadır. HER2 için hedefe yönelik tedavilerin başlamasıyla HER2 pozitif kanserli hastaların klinik gidişinde dramatik iyileşme sağlanmıştır. Günümüzde HER2 testi değişik yöntemlerle yapılmaktadır ve HER2 durumuna doğru değerlendirebilmek için bu testlerin standardizasyonu çok önemlidir. Bununla birlikte, onca yıllık deneyime karşın hem meme hem de mide tümörlerindeki HER2 değerlendirilmesinde hâlâ tartışmalı noktalar vardır. Bu derlemenin amacı HER2 değerlendirmesindeki tuzakları ve ipuçlarını irdelemektir.

🔖

Cite This Article

ÜNLÜ, A. G. D., IRKKAN, Ç., KELTEN, C., ÖZEKİNCİ, S. (2015). Clues and Pitfalls in the evaluation of HER2. İzmir Tepecik Eğitim Hastanesi Dergisi, Cilt: 25 - Sayı: 1, 7–12. https://ajindex.com/articles/213215

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Pala EE, Bayol Ü, Özgüzer A, Küçük Ü, Yıldız Akdeniz Ç, Sezer Ö. Meme kanserinde Her2 durumunu belirlemedeki sorunlar. J Breast Health 2015;11:10-16.
  2. Maguire HC, Greene MI. The neu (c-erbB-2) oncogene. Semin Oncol 1989;16(2):148-55
  3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235(4785):177-82.
  4. Irkkan SÇ. Mide kanserlerinde HER2 değerlendirmesi. Acta Oncologica Turcica 2014;47(3):42-51.
  5. Slamon DJ, Leyland-Jones B, Shak S, Fucks H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
  6. Paik S, Kim C, Wolmark N. Her2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 2008;358:1409-1411.
  7. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2- positive advanced breast cancer. N Engl J Med 2006;355(26):2733-43.
  8. Rüschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Penault-Lorca F, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol 2012;25(5):637-50.
  9. Gown AM: Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol 2008;21(2):8-15. PMID:18437174.
  10. Wolff AC, Hammond MEH, Schwartz JN, Hagerty KL, Allred DJ, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145.
  11. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013;31(31):3997-4013.
  12. Mansfield AS, Sukov WR, Eckel-Passow JE, Sakai Y, Walsh FJ, L